

THERAVANCE INC  
Form 8-K  
November 29, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

---

**Current Report Pursuant**  
**to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): **November 29, 2010**

---

**THERAVANCE, INC.**

(Exact Name of Registrant as Specified in its Charter)

---

**Delaware**

(State or Other Jurisdiction of  
Incorporation)

**000-30319**

(Commission File Number)

**94-3265960**

(I.R.S. Employer Identification Number)

Edgar Filing: THERAVANCE INC - Form 8-K

**901 Gateway Boulevard  
South San Francisco, California 94080  
(650) 808-6000**

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01. Entry into a Material Definitive Agreement.**

On November 29, 2010, Theravance, Inc., a Delaware corporation (the *Company*), entered into a Common Stock Purchase Agreement (the *Common Stock Purchase Agreement*) with Glaxo Group Limited, a limited liability company organized under the laws of England and Wales (the *Purchaser*) and, solely with respect to certain enumerated sections therein, GlaxoSmithKline LLC, a Delaware limited liability company, the successor entity to SmithKline Beecham Corporation, a Pennsylvania corporation (which, together with the *Purchaser*, is referred to as *GSK*). Pursuant to the terms of the *Common Stock Purchase Agreement*, the *Company* has agreed to sell 5,750,000 shares of its common stock (the *Shares*) to the *Purchaser* at a price of \$22.50 per share (the *Private Placement*). Upon completion of the *Private Placement*, *GSK* will own an aggregate of 15,151,499 shares of *Company* common stock and Class A common stock, which is equal to approximately 19% of the *Company*'s outstanding capital stock. The foregoing is a summary of the terms of the *Common Stock Purchase Agreement* and is qualified in its entirety by reference to the *Common Stock Purchase Agreement*, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On November 29, 2010, in connection with signing the *Common Stock Purchase Agreement*, the *Company* entered into a Second Amendment to Amended and Restated Governance Agreement with GlaxoSmithKline LLC, GlaxoSmithKline plc and the *Purchaser* (the *Second Amendment*). The *Second Amendment* provides that if the *Company* shall convert into voting stock the unsecured convertible subordinated notes issued by the *Company* in January 2008, then GlaxoSmithKline LLC shall have notice rights and a right to purchase additional shares of voting stock to maintain its percentage ownership interest before the conversion. The foregoing is a summary of the terms of the *Second Amendment* and is qualified in its entirety by reference to the *Second Amendment*, a copy of which is attached as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 3.02. Unregistered Sales of Equity Securities.**

The information set forth in Item 1.01 of this Current Report on Form 8-K that relates to an agreement to sell unregistered equity securities of the *Company* in a private placement is incorporated herein by reference. The *Private Placement* is scheduled to close on November 29, 2010. The *Private Placement* will result in aggregate gross proceeds of \$129,375,000 before deducting transaction expenses. Neither the *Company* nor the *Purchaser* engaged any investment advisors with respect to the *Private Placement*, and no finders' fees will be paid to any party in connection therewith. The *Shares* will be issued and sold by the *Company* in reliance upon an exemption from registration pursuant to Rule 4(2) of the Securities Act of 1933, as amended.

**Item 8.01. Other Events.**

On November 29, 2010, the *Company* and GlaxoSmithKline plc issued a joint press release announcing the signing of the *Common Stock Purchase Agreement*. A copy of the joint press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) *Exhibits.*

Edgar Filing: THERAVANCE INC - Form 8-K

Exhibit Number	Description
10.1	Common Stock Purchase Agreement, dated November 29, 2010, by and among Theravance, Inc., Glaxo Group Limited and GlaxoSmithKline LLC
10.2	Second Amendment to Amended and Restated Governance Agreement, dated November 29, 2010, which amends the Amended and Restated Governance Agreement dated June 4, 2004, as previously amended May 11, 2007, by and among Theravance, Inc., GlaxoSmithKline LLC and GlaxoSmithKline plc
99.1	Joint Press Release, dated November 29, 2010, issued by Theravance, Inc. and GlaxoSmithKline plc

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**THERAVANCE, INC.**

Dated: November 29, 2010

By:

/s/ Bradford J. Shafer

**Bradford J. Shafer**

**Sr. Vice President, General Counsel and Secretary**